Core Points - Addex Therapeutics has issued 34,300,000 new registered shares at a nominal value of CHF 0.01, fully subscribed by its wholly-owned subsidiary, Addex Pharma S.A, to enhance future financing flexibility [1] - The total issued share capital has increased to CHF 2,186,544.96, with a total of 218,654,496 shares issued, while the number of outstanding shares remains unchanged [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2] - Addex has partnered with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [2] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [2] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Market Overview - U.S. stock futures are higher, with Dow futures gaining approximately 0.2% on Monday [1] Company-Specific Movements - Olema Pharmaceuticals Inc (NASDAQ:OLMA) shares fell 18.3% to $7.64 in pre-market trading following the announcement of new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO 2025 [1] - Concord Medical Services Hldgs Ltd (NYSE:CCM) experienced a decline of 24.4% to $4.15 in pre-market trading after a 6% drop on Friday [3] - Addex Therapeutics Ltd – ADR (NASDAQ:ADXN) dipped 15.6% to $9.23 in pre-market trading after a significant gain of 28% on Friday [3] - Exelixis Inc (NASDAQ:EXEL) shares fell 8.3% to $36.00 after announcing detailed results from the Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer, presented at ESMO 2025 and published in The Lancet [3] - Cellectis SA (NASDAQ:CLLS) shares declined 7.3% to $3.69 in pre-market trading [3] - Alumis Inc (NASDAQ:ALMS) saw a decline of 6.7% to $4.19 in pre-market trading [3] - Nanobiotix SA – ADR (NASDAQ:NBTX) fell 6.3% to $23.98 in pre-market trading after a 4% decline on Friday [3] - Genmab A/S – ADR (NASDAQ:GMAB) declined 4.1% to $31.81 in pre-market trading, with Rinatabart Sesutecan achieving a 50% objective response rate and two complete responses in advanced endometrial cancer [3] - Taysha Gene Therapies Inc (NASDAQ:TSHA) fell 4% to $4.53 in pre-market trading [3]

Financial Data and Key Metrics Changes - The company completed H1 2025 with cash of CHF 2.3 million, providing a runway through mid-2026 [6] - Income decreased by $100,000 in Q2 2025 compared to Q2 2024, amounting to $100,000, primarily due to the completion of the funded research phase with Indivior [18] - R&D expenses of $200,000 in Q2 2025 decreased by $100,000 compared to Q2 2024, mainly due to the completion of the research phase with Indivior [19] - G&A expenses of $500,000 decreased by $100,000 in Q2 2025 compared to Q2 2024, primarily due to decreased legal fees [19] - Current liabilities increased by $300,000 compared to December 2024, primarily due to increased payables [20] Business Line Data and Key Metrics Changes - The GABA B PAM program has made significant progress, with IND enabling studies completed by the partner Indivior for substance use disorders [21] - The company has advanced its independent GABA B PAM program for chronic cough and is ready to start IND enabling studies, subject to securing financing [21] - The repositioning of diproglurant for brain injury recovery has been initiated, with an exclusive license agreement for mGluR5 inhibitors [5] Market Data and Key Metrics Changes - The chronic cough market presents a large unmet medical need, with current treatments ineffective in 30% of patients and only moderately effective in up to 60% [12] - The company believes that GABA B PAMs could offer superior efficacy in chronic cough patients compared to current standards of care [12] Company Strategy and Development Direction - The company is focused on advancing its GABA B PAM program and has regained rights to its mGluR2 positive allosteric modulator program [4] - The strategic objective includes validating partnerships with industry and supportive investors while maintaining a strong balance sheet [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the renewed interest in the neuropsychiatry space, highlighting recent transactions and the potential for Neurosterics and Stellicla [25] - The company is actively pursuing financing strategies for Stellicla, which is focused on patient stratification technology [26] Other Important Information - The company has invested in Stellicla, which has developed a precision medicine platform for neurodevelopmental disorders [5] - The IND enabling studies for the GABA B PAM program are planned to start this year, with promising preclinical data [16] Q&A Session Summary Question: Recent developments in the neuropsychiatry space and implications for Neurosterics and Stellicla - Management noted renewed excitement in the neuropsychiatry space and highlighted the successful financing of Neurosterics [25][26] Question: Insights into long-acting injectable formulations for Neurosterics - Management indicated that while they cannot speculate, there is potential for longer-acting formulations in the m4 PAM space due to compliance issues [30][31] Question: Ideal target patient population for the chronic cough program - Management stated that the GABA B PAMs were selected to maximize the range of chronic cough patients, focusing on centrally acting compounds [33]

Addex Therapeutics │ Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2025, and December 31, 2024 | | | June 30, | December 31, | | --- | --- | --- | --- | | | Notes | 2025 Amounts in Swiss francs | 2024 | | ASSETS | | | | | Current assets | | | | | Cash and cash equivalents | 6 | 2,300,994 | 3,341,738 | | Other financial assets | 7/13 | 6,994 | 6,496 | | Trade and other receivables | 7 | 38,439 | 15,513 | | Prepayments | 7 ...

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, reflecting a decrease of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, an improvement of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [11] Cash Position - Cash and cash equivalents decreased to CHF 2.3 million as of June 30, 2025, down from CHF 3.8 million as of June 30, 2024, a decrease of CHF 1.5 million [7][11] Corporate Developments - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - The company regained rights to the Phase 2 mGlu2 PAM asset, ADX71149, and is evaluating next steps internally [2][5] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - The company invested in Stalicla, reinforcing its commitment to innovative treatments for CNS disorders [2][5][16]

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, an improvement of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, a decrease of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [7][11] - Cash position decreased to CHF 2.3 million at the end of H1 2025 from CHF 3.8 million at the end of H1 2024 [5][11] Operational Highlights - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - Rights to the Phase 2 mGlu2 PAM asset, ADX71149, were regained, with internal evaluations for next steps ongoing [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6] - Investment in Stalicla SA was made, reinforcing the commitment to innovative treatments for CNS disorders [5][6][16]

Core Viewpoint - Addex Therapeutics is set to report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025, followed by a conference call on October 1, 2025, to discuss the results and provide a business update [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3]. - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3]. - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3]. Upcoming Events - The conference call to discuss the financial results will take place on October 1, 2025, at 16:00 CEST, with participation from CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev [1][2].

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] Recent Developments - Addex Therapeutics announced the appointment of the Bank of New-York Mellon (BNY) as its new ADS depositary agent, effective October 6, 2025 [1] - The appointment of BNY will not impact the fees paid by ADS holders, and no action is required from them at the effective date [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares are listed on the NASDAQ Capital Market under the ticker symbol "ADXN" [3]

Core Insights - Addex Therapeutics has made a strategic investment of CHF 2 million in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [1][2] - The investment aims to support Stalicla's portfolio of autism-focused drug candidates and its series C financing, while also enhancing Addex's commitment to advancing innovative treatments for CNS disorders [2][3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a lead drug candidate, dipraglurant, under evaluation for brain injury recovery [4] - Stalicla has raised over $50 million in equity and more than $30 million in non-dilutive funding, focusing on transforming treatments for neurodevelopmental disorders [3][4] Investment Details - The investment will enable Stalicla to advance its lead autism candidate STP1 and a second asset into Phase 2 trials, targeting specific subpopulations within autism spectrum disorder (ASD) [2][3] - Stalicla is also progressing its STP7 program (mavoglurant) for cocaine use disorders, which is the most advanced treatment candidate in development for this indication [2][3] Leadership Changes - As part of the investment, Addex CEO Tim Dyer has been appointed to Stalicla's Board of Directors and nominated as Chairman, indicating a deeper collaboration between the two companies [1][2]

Core Insights - Stalicla SA has successfully closed a CHF 2 million financing round led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders [1][2] - The financing will support Stalicla's operations and program development as it prepares for a Series C financing and partnerships for key programs [1][2] - Stalicla's DEPI precision neuro platform and its autism assets, STP1 and STP2, have garnered investor confidence, while the STP7 program (mavoglurant) is progressing towards Phase 3 trials [1][3] Company Overview - Stalicla SA is a clinical-stage biopharmaceutical company based in Switzerland, having raised over $50 million in equity and more than $30 million in non-dilutive funding to enhance treatments for neurodevelopmental disorders [3] - The company has developed a neuro precision development platform that identifies stratified patient subgroups, facilitating personalized treatment options [3] - Stalicla is preparing to initiate Phase 2 trials for its leading asset, STP1, targeting specific subpopulations within autism, while STP7 is advancing towards Phase 3 trials with funding from the US government [3] Leadership and Strategic Direction - Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman, indicating a strategic partnership with Addex Therapeutics [2] - Lynn Durham, CEO of Stalicla, emphasized the importance of this financing in reaching significant milestones, including transformative clinical trials in autism and substance use disorders [2] - Addex Therapeutics recognizes Stalicla's platform as world-leading in precision medicine for neurodevelopmental disorders and aims to support the advancement of these critical medicines [2]